For: | Guo YT, Leng XS, Li T, Zhao JM, Lin XH. Peroxisome proliferator-activated receptor γ ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats. World J Gastroenterol 2004; 10(23): 3419-3423 [PMID: 15526359 DOI: 10.3748/wjg.v10.i23.3419] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i23/3419.htm |
Number | Citing Articles |
1 |
Xishan Xiong, Yangliang Ye, Lili Fu, Bing Dai, Jieqiong Liu, Jieshuang Jia, Jing Tang, Lin Li, Li Wang, Jianhua Shen, Changlin Mei. Antitumor activity of a novel series of α-aryloxy-α-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Investigational New Drugs 2009; 27(3): 223 doi: 10.1007/s10637-008-9161-0
|
2 |
Shugo Suzuki, Yukiko Mori, Aya Nagano, Aya Naiki-Ito, Hiroyuki Kato, Yuko Nagayasu, Mizuho Kobayashi, Toshiya Kuno, Satoru Takahashi. Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. International Journal of Molecular Sciences 2016; 17(12): 2071 doi: 10.3390/ijms17122071
|
3 |
Romi Ghose, Jaap Mulder, Richard J. von Furstenberg, Sundararajah Thevananther, Folkert Kuipers, Saul J. Karpen. Rosiglitazone attenuates suppression of RXRα-dependent gene expression in inflamed liver. Journal of Hepatology 2007; 46(1): 115 doi: 10.1016/j.jhep.2006.09.008
|
4 |
Xishan Xiong, Li Wang, Yangliang Ye, Lili Fu, Minli Chen, Qingyi Wang, Moyan Liu, Jing Tang, Bing Dai, Jianhua Shen, Changlin Mei. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents. Investigational New Drugs 2010; 28(4): 472 doi: 10.1007/s10637-009-9278-9
|
5 |
Bianka Bojková, Miroslava Garajová, Karol Kajo, Martin Péč, Peter Kubatka, Monika Kassayová, Terézia Kisková, Peter Orendáš, Eva Ahlersová, Ivan Ahlers. Pioglitazone in chemically induced mammary carcinogenesis in rats. European Journal of Cancer Prevention 2010; 19(5): 379 doi: 10.1097/CEJ.0b013e32833ca233
|
6 |
I. Borbath, I. Leclercq, P. Moulin, C. Sempoux, Y. Horsmans. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. European Journal of Cancer 2007; 43(11): 1755 doi: 10.1016/j.ejca.2007.05.005
|
7 |
D. Hattis, M. Chu, N. Rahmioglu, R. Goble, P. Verma, K. Hartman, M. Kozlak. A Preliminary Operational Classification System for Nonmutagenic Modes of Action for Carcinogenesis. Critical Reviews in Toxicology 2009; 39(2): 97 doi: 10.1080/10408440802307467
|
8 |
Yian Wang, Michael James, Weidong Wen, Yan Lu, Eva Szabo, Ronald A. Lubet, Ming You. Chemopreventive Effects of Pioglitazone on Chemically Induced Lung Carcinogenesis in Mice. Molecular Cancer Therapeutics 2010; 9(11): 3074 doi: 10.1158/1535-7163.MCT-10-0510
|
9 |
George G. Harrigan, Jerry Colca, Sándor Szalma, László G. Boros. PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells. Metabolomics 2006; 2(1): 21 doi: 10.1007/s11306-006-0015-5
|
10 |
Ivan Borbath, Yves Horsmans, Dipak Panigrahy. The Role of PPARγ in Hepatocellular Carcinoma. PPAR Research 2008; 2008(1) doi: 10.1155/2008/209520
|
11 |
Bianka Bojková, Peter Orendáš, Peter Kubatka, Martin Péč, Monika Kassayová, Terézia Kisková, Karol Kajo. Positive and negative effects of glitazones in carcinogenesis: Experimental models vs. clinical practice. Pathology - Research and Practice 2014; 210(8): 465 doi: 10.1016/j.prp.2014.06.003
|